Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00005878
Other study ID # JHOC-J9932, CDR0000067917
Secondary ID P30CA006973JHOC-
Status Completed
Phase Phase 2
First received June 2, 2000
Last updated October 12, 2016
Start date July 2000
Est. completion date September 2005

Study information

Verified date October 2016
Source Sidney Kimmel Comprehensive Cancer Center
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Celecoxib may be effective in preventing cancer in patients with Barrett's esophagus.

PURPOSE: Randomized phase II trial to study the effectiveness of celecoxib in preventing cancer in patients who have Barrett's esophagus.


Description:

OBJECTIVES:

- Determine the safety and efficacy of celecoxib for regression of Barrett's dysplasia in patients with low or high-grade dysplasia of the esophagus.

OUTLINE: This is a randomized, parallel, double-blind, placebo-controlled, multicenter study. Patients are stratified according to center and grade of dysplasia at baseline (low vs high). Patients are randomized to one of two treatment arms.

- Arm I: Patients receive oral celecoxib twice daily for 48-96 weeks.

- Arm II: Patients receive oral placebo as in arm I. Treatment continues in both arms in the absence of unacceptable toxicity or development of adenocarcinoma of the esophagus or cancer at other sites.

Patients are followed at 12 weeks.

PROJECTED ACCRUAL: A total of 200 patients (100 per arm) will be accrued for this study.


Recruitment information / eligibility

Status Completed
Enrollment 0
Est. completion date September 2005
Est. primary completion date September 2005
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 120 Years
Eligibility DISEASE CHARACTERISTICS:

- Histologically confirmed Barrett's dysplasia with specific information on the location (level) of the highest grade of dysplasia based on biopsy from baseline endoscopy

- Short segment Barrett's esophagus must be sufficient area to allow for biopsy without complete resection

- No presence of reflux esophagitis grades 2-4

- No history of confirmed invasive carcinoma of the esophagus

- No diagnosis of esophageal, gastric, pyloric channel, or duodenal ulceration of 1 cm or more in diameter within the past 30 days

PATIENT CHARACTERISTICS:

Age:

- 18 and over

Performance status:

- ECOG 0-2

Life expectancy:

- Not specified

Hematopoietic:

- Hemoglobin at least 9 g/dL

- Platelet count greater than 125,000/mm^3

- WBC greater than 3,000/mm^3

- No significant bleeding disorder

- No other abnormal hematopoietic laboratory test result that would preclude study

Hepatic:

- PT/PTT no greater than 1.5 times upper limit of normal (ULN)

- AST/ALT less than 1.5 times ULN

- Alkaline phosphatase less than 1.5 times ULN

- No chronic or acute hepatic disorder

- No abnormal hepatic laboratory test result that would preclude study

Renal:

- Creatinine no greater than 1.5 times ULN

- No chronic or acute renal disorder

- No other abnormal renal laboratory test result that would preclude study

Other:

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No prior or concurrent active inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis)

- No other prior or concurrent curatively treated malignancy with a survival prognosis of less than 5 years

- No hypersensitivity or adverse reaction to COX-2 inhibitors (e.g., celecoxib), sulfonamides, salicylates, or NSAIDs

- No other significant medical, psychological, or psychosocial condition that would preclude study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- Not specified

Chemotherapy:

- Not specified

Endocrine therapy:

- At least 6 months since prior regular (at least 2 weeks duration) oral or intravenous corticosteroids

- At least 6 months since prior regular (at least 4 weeks duration) inhaled corticosteroids

- No concurrent regular oral or intravenous corticosteroids

- No concurrent regular inhaled corticosteroids

- Concurrent corticosteroid nasal spray allowed

Radiotherapy:

- At least 12 weeks since prior radiotherapy to the chest or upper abdomen

Surgery:

- At least 3 months since prior surgery to the esophagus or stomach except hiatal hernia repair, fundoplication, vagotomy, or pyloroplasty

- No prior complete mucosal resection using any technique

- No concurrent resection of high-grade nodule

Other:

- At least 30 days since prior chronic (at least 3 times a week for greater than 2 weeks) aspirin or other nonsteroidal antiinflammatory drugs (NSAIDs) (i.e., greater than 100 mg/day)

- No prior complete mucosal ablation using any technique

- No prior treatment on this study

- At least 30 days since prior investigational medication including shingles vaccine

- No concurrent chronic NSAIDs or COX-2 inhibitors except low-dose aspirin (i.e., no greater than 100 mg/day)

- No concurrent anticoagulants (e.g., heparin or warfarin)

- No other concurrent investigational medication

Study Design

Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
celecoxib


Locations

Country Name City State
United States Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore Maryland
United States Ireland Cancer Center Cleveland Ohio
United States Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital) Hines Illinois
United States Jonsson Comprehensive Cancer Center, UCLA Los Angeles California
United States Herbert Irving Comprehensive Cancer Center New York New York
United States Veterans Affairs Medical Center - Portland Portland Oregon
United States Mayo Clinic Cancer Center Rochester Minnesota
United States Veterans Affairs Medical Center - Tucson Tucson Arizona

Sponsors (2)

Lead Sponsor Collaborator
Sidney Kimmel Comprehensive Cancer Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Heath EI, Canto MI, Piantadosi S, Montgomery E, Weinstein WM, Herman JG, Dannenberg AJ, Yang VW, Shar AO, Hawk E, Forastiere AA; Chemoprevention for Barrett's Esophagus Trial Research Group. Secondary chemoprevention of Barrett's esophagus with celecoxib: — View Citation

See also
  Status Clinical Trial Phase
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
Not yet recruiting NCT05542680 - Study on the Design and Application of Special Semi Recumbent Cushion for Postoperative Patients With Esophageal Cancer N/A
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Completed NCT00003864 - Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus Phase 2
Recruiting NCT05491616 - Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Completed NCT00199849 - NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Phase 1
Completed NCT03756597 - PAN-study: Pan-Cancer Early Detection Study (PAN)
Completed NCT00400114 - Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer Phase 2
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Recruiting NCT04615806 - The Value of Lymph Node Dissection of Indocyanine Green-guided Near-infrared Fluorescent Imaging in Esophagectomy N/A
Active, not recruiting NCT04566367 - Blue Laser Imaging (BLI) for Detection of Secondary Head and Neck Cancer N/A
Active, not recruiting NCT03962179 - Feasibility and Efficacy of a Combination of a SEMS and Vacuum Wound Treatment (VACStent) N/A
Terminated NCT01446874 - Prevention of Post-operative Pneumonia (POPP) Phase 2/Phase 3
Completed NCT03468634 - Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy N/A
Active, not recruiting NCT02869217 - Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors Phase 1
Completed NCT02810652 - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection N/A
Recruiting NCT02544737 - Apatinib for Metastatic Esophageal Cancer. Phase 2